---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-019049"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2022-07-12T23:59:59+00:00"
generated_at: "2026-06-24T16:41:21.009279+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix doses first subjects in Phase 1 trial of inhaled DHE (PUR3100) for acute migraine

## Summary
- First five subjects dosed in Phase 1 trial of PUR3100, an inhaled formulation of dihydroergotamine (DHE) using iSPERSE technology.
- Phase 1 is a double-dummy, double-blinded trial assessing safety, tolerability, and PK of 3 inhaled doses vs IV DHE in 24 healthy volunteers.
- Data including safety, tolerability, and pharmacokinetics expected in Q4 2022 to guide dose selection for registration-enabling studies.
- Dr. Margaret Wasilewski, CMO, cited oral inhalation as potentially more convenient than IV or nasal DHE with fewer side effects.

## SEC filing metadata
- accession: 0001493152-22-019049
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2022-07-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315222019049/0001493152-22-019049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315222019049/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-019049
- JSON: https://secwatch.observer/filing/0001493152-22-019049.json
- Plain text: https://secwatch.observer/filing/0001493152-22-019049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.